,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-07-18 06:46:00,"Medical devices major, St. Jude Medical, Inc. 's ( STJ ) second quarter 2012 adjusted earnings of 88 cents per share beat the Zacks Consensus Estimate by a penny and surpassed the year-ago earnings of 85 cents per share.",0.9469465017318726,0.03294378146529198,0.02010977827012539,positive,0.9140027165412903
1,2012-07-18 06:46:00,Earnings were in line with the company's previously announced guidance.,0.8733908534049988,0.019290566444396973,0.10731859505176544,positive,0.8541002869606018
2,2012-07-18 06:46:00,Adjusted earnings exclude extraordinary and one-time charges such as restructuring expenses to modernize manufacturing at the Cardiac Rhythm Management (CRM) segment; costs associated with improvement of its sales force and an income tax benefit.,0.04237329587340355,0.03600052371621132,0.9216261506080627,neutral,0.00637277215719223
3,2012-07-18 06:46:00,"In the reported quarter, profits inched up 1.2% to $244 million (or 78 cents a share) as lower expenses offset weak revenue generation.",0.9403553009033203,0.042356789112091064,0.017287973314523697,positive,0.8979985117912292
4,2012-07-18 06:46:00,"St. Jude reported net revenues of $1,410 million, down 2% year over year.",0.01745445467531681,0.9710968136787415,0.011448859237134457,negative,-0.9536423683166504
5,2012-07-18 06:46:00,"Revenues missed the Zacks Consensus Estimate of $1,430 million.",0.021520275622606277,0.9618004560470581,0.016679318621754646,negative,-0.9402801990509033
6,2012-07-18 06:46:00,Net sales rose 1% on constant currency basis.,0.9555867910385132,0.018784604966640472,0.02562868781387806,positive,0.9368022084236145
7,2012-07-18 06:46:00,Continued poor performance across the CRM unit and lower vascular product sales more than offset growth at the company's smaller Atrial Fibrillation (AF) and Neuromodulation franchises.,0.023399531841278076,0.9645503163337708,0.01205019373446703,negative,-0.9411507844924927
8,2012-07-18 06:46:00,"On a geographic basis, revenues from the domestic and international markets were $664 million (down 2%) and $746 million (down 3%), respectively.",0.020570112392306328,0.6844203472137451,0.2950095534324646,negative,-0.6638502478599548
9,2012-07-18 06:46:00,Revenues from the core CRM business dropped 6% year over year (down 3% in terms of constant currency) to $746 million.,0.0162738636136055,0.9736440777778625,0.010082026943564415,negative,-0.9573702216148376
10,2012-07-18 06:46:00,"Within CRM, revenues from Implantable Cardioverter Defibrillator (ICD) declined 4% (down 1% in constant currency) to $459 million.",0.019870908930897713,0.9717294573783875,0.008399666287004948,negative,-0.9518585205078125
11,2012-07-18 06:46:00,Sales from the pacemaker division dipped 9% (down 5% in constant currency) to $287 million.,0.018106738105416298,0.9724159836769104,0.009477282874286175,negative,-0.9543092250823975
12,2012-07-18 06:46:00,"On a positive note, AF sales increased 5% (up 8% in constant currency) to $218 million in the quarter.",0.9599632620811462,0.018525071442127228,0.021511636674404144,positive,0.9414381980895996
13,2012-07-18 06:46:00,"Neuromodulation sales rose 2%, (up 5% in constant currency) year over year to $106 million.",0.9589947462081909,0.020035428926348686,0.02096976898610592,positive,0.9389593005180359
14,2012-07-18 06:46:00,Revenues from St. Jude's Cardiovascular segment inched down 1% (up 3% in constant currency) to $340 million.,0.01839534193277359,0.9709161520004272,0.010688493959605694,negative,-0.9525207877159119
15,2012-07-18 06:46:00,"Within the Cardiovascular segment, structural heart devices sales increased 5% to $160 million offset by revenues from vascular offerings, which fell 5% year over year to $180 million.",0.1359008550643921,0.8448254466056824,0.019273661077022552,negative,-0.7089245915412903
16,2012-07-18 06:46:00,Gross margin remained roughly flat year over year at 72.8%.,0.03386798873543739,0.8582631945610046,0.10786876082420349,negative,-0.8243951797485352
17,2012-07-18 06:46:00,"Selling, general and administrative expenses, as a percentage of sales, edged down to 35% from 35.5% a year ago.",0.019303487613797188,0.9718688130378723,0.008827653713524342,negative,-0.9525653123855591
18,2012-07-18 06:46:00,"Research and development expenses (as a percentage of sales) were 12.3%, flat year over year.",0.020745782181620598,0.9482693672180176,0.030984852463006973,negative,-0.9275236129760742
19,2012-07-18 06:46:00,Operating margins increased to 24% from 22.5% a year ago.,0.9604580402374268,0.02450789324939251,0.015034036710858345,positive,0.9359501600265503
20,2012-07-18 06:46:00,"St. Jude exited second quarter 2012 with cash and cash equivalents of $1,214 million, 45.7% higher than the previous year.",0.9328534603118896,0.021119212731719017,0.04602731019258499,positive,0.9117342233657837
21,2012-07-18 06:46:00,"Long-term debt (including current obligations) increased 15.4% year over year to $2,963 million.",0.9579287767410278,0.01871577464044094,0.023355450481176376,positive,0.9392129778862
22,2012-07-18 06:46:00,St. Jude recently announced the launch of its Unify Quadra cardiac resynchronization therapy defibrillator (CRT-D) in Japan to treat heart failure.,0.7139424085617065,0.010511090978980064,0.27554643154144287,positive,0.7034313082695007
23,2012-07-18 06:46:00,The company also announced early phase-I results of its Riata Lead Evaluation Study.,0.2867582142353058,0.008399510756134987,0.704842209815979,neutral,0.27835869789123535
24,2012-07-18 06:46:00,It was found that externalized conductors occurred less frequently in Riata ST 7F with a small diameter in comparison to the thicker Riata 8F leads.,0.11826261132955551,0.38612282276153564,0.49561458826065063,neutral,-0.26786020398139954
25,2012-07-18 06:46:00,Management asserted that the results are consistent with other published studies.,0.2395654320716858,0.013464236631989479,0.7469702959060669,neutral,0.22610118985176086
26,2012-07-18 06:46:00,The company's Leads Medical Advisory Board did not make any changes to existing patient management recommendations.,0.021266436204314232,0.07408425956964493,0.9046492576599121,neutral,-0.05281782150268555
27,2012-07-18 06:46:00,Also worth mentioning in this context is the limited impact of negative data on Durata on the company's performance during the reported quarter.,0.030229495838284492,0.07250899076461792,0.8972615003585815,neutral,-0.04227949678897858
28,2012-07-18 06:46:00,"However, we are wary of investor reactions due to the highly sensitive nature of the product in the soft ICD market.",0.031618617475032806,0.22053547203540802,0.7478458881378174,neutral,-0.1889168620109558
29,2012-07-18 06:46:00,"During the quarter, St. Jude's Cardiovascular business achieved two milestones.",0.9361894130706787,0.016566310077905655,0.047244325280189514,positive,0.919623076915741
30,2012-07-18 06:46:00,"In May, the company received the CE Mark approval for its EnligHTN renal denervation system for treating patients with hypertension.",0.8907378315925598,0.013315324671566486,0.09594684839248657,positive,0.8774225115776062
31,2012-07-18 06:46:00,"Also in June 2012, the company announced U.S. Food and Drug Administration (FDA) approval for its Amplatzer Vascular Plug 4 (""AVP4"") device in the U.S.

For full-year 2012, St. Jude lowered its adjusted earnings forecast to the range of $3.40 - $3.45 per share from the earlier band of $3.44 - $3.49.",0.025409212335944176,0.9529218077659607,0.02166895568370819,negative,-0.9275125861167908
32,2012-07-18 06:46:00,"On a reported basis, the company expects earnings to be in the range of $3.00 - $3.05 per share.",0.08318103104829788,0.006666145287454128,0.910152792930603,neutral,0.07651488482952118
33,2012-07-18 06:46:00,"For the third quarter, the company expects adjusted earnings in the band of 80 cents - 82 cents a share.",0.42743852734565735,0.014005535282194614,0.5585559010505676,neutral,0.4134329855442047
34,2012-07-18 06:46:00,"On a reported basis, the company expects earnings to be between 74 cents and 76 cents for the third quarter.",0.09649311751127243,0.008746015839278698,0.8947609066963196,neutral,0.08774710446596146
35,2012-07-18 06:46:00,"While a host of new growth drivers (including new products and cost saving measures) are expected to boost results in 2013 and beyond, we remain cautious about increased competition, restructuring expenses within the CRM business and the overall soft CRM market.",0.7813711762428284,0.12648195028305054,0.09214688092470169,positive,0.6548892259597778
36,2012-07-18 06:46:00,A still choppy CRM space is a cause of concern for St. Jude and its peers Medtronic ( MDT ) and Boston Scientific ( BSX ).,0.022773411124944687,0.9577770829200745,0.01944953389465809,negative,-0.9350036978721619
37,2012-07-18 06:46:00,Our long-term Neutral recommendation on St. Jude is in agreement with a short-term Zacks #3 Rank (Hold).,0.5755994915962219,0.016510769724845886,0.407889723777771,positive,0.5590887069702148
38,2012-07-18 06:46:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
39,2012-07-18 06:46:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
